KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures: 2016-2024

Historic Gains from Sales and Divestitures for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Dec 2024 value amounting to $450,701.

  • CRISPR Therapeutics AG's Gains from Sales and Divestitures rose 52.05% to $590,587 in Q3 2025 from the same period last year, while for Sep 2025 it was $590,587, marking a year-over-year increase of 52.05%. This contributed to the annual value of $450,701 for FY2024, which is 62.23% up from last year.
  • As of FY2024, CRISPR Therapeutics AG's Gains from Sales and Divestitures stood at $450,701, which was up 62.23% from $277,808 recorded in FY2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Gains from Sales and Divestitures peaked at $455,440 during FY2021, and registered a low of $204,650 during FY2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $277,808 (2023), whereas its average is $322,147.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Gains from Sales and Divestitures spiked by 135.89% in 2020 and then slumped by 47.76% in 2022.
  • CRISPR Therapeutics AG's Gains from Sales and Divestitures (Yearly) stood at $204,650 in 2020, then soared by 122.55% to $455,440 in 2021, then tumbled by 47.76% to $237,932 in 2022, then rose by 16.76% to $277,808 in 2023, then surged by 62.23% to $450,701 in 2024.